ZLD · ASX

Zelira Therapeutics Ltd. (ASX:ZLD)

AU$0.39

 0.0 (0.0%)
ASX:Live
17/04/2025 11:42:00 AM
Near Support HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ZLD Overview

ZLD Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ZLD

Telephone

Address

Description

Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.

ZLD Price Chart

Key Stats

Market Cap

AU$4.64M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.28 - 1.09

Trade Value (12mth)

AU$782.00

1 week

-17.02%

1 month

-17.02%

YTD

-37.1%

1 year

-45.83%

All time high

20453.10

Key Fundamentals

EPS 3 yr Growth

150.20%

EBITDA Margin

%

Operating Cashflow

-$4m

Free Cash Flow Return

-31.60%

ROIC

-263.70%

Interest Coverage

-7.70

Quick Ratio

0.40

Other Data

Shares on Issue (Fully Dilluted)

11m

HALO Sector

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ZLD Announcements

Latest Announcements

Date Announcements

03 April 25

Investor Presentation

×

Investor Presentation

01 April 25

Application for quotation of securities - ZLD

×

Application for quotation of securities - ZLD

31 March 25

Zelira secures $1 Million At-the-Market Funding Facility

×

Zelira secures $1 Million At-the-Market Funding Facility

31 March 25

Proposed issue of securities - ZLD

×

Proposed issue of securities - ZLD

31 March 25

Cleansing Prospectus

×

Cleansing Prospectus

26 February 25

Appendix 4D & FY25 Interim Financial Report

×

Appendix 4D & FY25 Interim Financial Report

18 February 25

Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund

×

Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund

30 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 January 25

Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche

×

Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche

20 January 25

Change of Director's Interest Notice x 2

×

Change of Director's Interest Notice x 2

17 January 25

Notification of cessation of securities - ZLD

×

Notification of cessation of securities - ZLD

19 December 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

18 December 24

Notification regarding unquoted securities - ZLD

×

Notification regarding unquoted securities - ZLD

20 November 24

Zelira to present at Automic Invest 2024 conference

×

Zelira to present at Automic Invest 2024 conference

14 November 24

2024 Annual General Meeting Presentation

×

2024 Annual General Meeting Presentation

14 November 24

Results of Meeting

×

Results of Meeting

14 November 24

Proposed issue of securities - ZLD

×

Proposed issue of securities - ZLD

29 October 24

September 2024 Quarterly Activities Report

×

September 2024 Quarterly Activities Report

29 October 24

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

11 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

11 October 24

Letter to Shareholders

×

Letter to Shareholders

20 September 24

Investor Webinar - HOPE FDA Program Update

×

Investor Webinar - HOPE FDA Program Update

18 September 24

Notice of Investor Webinar - HOPE FDA Program Update

×

Notice of Investor Webinar - HOPE FDA Program Update

12 September 24

AGM Date and Closing Date for Director Nominations

×

AGM Date and Closing Date for Director Nominations

28 August 24

Appendix 4E and Financial Report to Shareholders

×

Appendix 4E and Financial Report to Shareholders

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ZLD Shortsell

Frequently Asked Questions

The current share price of Zelira Therapeutics Ltd. (ZLD:ASX) is AU$0.39.
The 52-week high share price for Zelira Therapeutics Ltd. (ZLD:ASX) is AU$1.09.
The 52-week low share price for Zelira Therapeutics Ltd. (ZLD:ASX)? is AU$0.28.
Zelira Therapeutics Ltd. (ZLD:ASX) does not pay a dividend.
Zelira Therapeutics Ltd. (ZLD:ASX) does not pay a dividend.
Zelira Therapeutics Ltd. (ZLD:ASX) does not offer franking credits.
Zelira Therapeutics Ltd. (ZLD:ASX) is classified in the Healthcare.
The current P/E ratio for Zelira Therapeutics Ltd. (ZLD:ASX) is .